112 results about "Liver transplantation" patented technology

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.

The invention relates to a portable liver extracorporal charging preservation apparatus for liver transplantation comprising a constant temperature water bath tank for liver storage, an oxygenator, a hepatic artery charging circulation loop and a portal vein charging circulation loop, and an intelligent control device for controlling bath tank temperature and flow capacity of charging circulation loop. The liver dual perfusion model created by the invention can carry out oxygen cycle charging to the exsomatized liver at normothermia.

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

The invention relates to a realization method of a computer-assisted liver transplantation operation planning system, comprising the following steps: step 1, establishing a normal person liver shape library; step 2, for the liver to be operated, modeling the initial partition result of the liver area by using a method based on sparse representation, and eliminating disturbance of singular point and noise data, so as to obtain a prior shape having a liver area with patient adaptability; steps 3, precisely partitioning the liver by utilizing the prior shape, and simultaneously separating out liver parenchyma, portal vein, liver vein and tumour; step 4, dividing the liver into eight liver segments independent in functions by utilizing the liver vein partition result, and calculating the volume of each liver segment and the tumour; and step 5, carrying out 3D visualization on the partitioning and segmenting result. Compared with the prior art, the realization method has the advantages of high precision and robustness, convenience in realization and capability of treating complicated liver shapes.

Disclosed is a method for diagnosing whether a subject suffers from a mild or severe form of liver cirrhosis based on determining the amount of GDF-15 (growth differentiation factor 15), PlGF (placental growth factor), and/or hepatocyte growth factor (HGF) in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts). The method may further include determining the amount of adiponectin in a sample from the subject, and comparing the amount to a reference amount for adiponectin. Also described is a method to identifying a subject being susceptible to liver transplantation including determining the amount of GDF-15, PlGF, and/or HGF in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts).

Hepatic ischemic reperfusion injury is a major complication of liver transplantation, resectional hepatic surgeries, trauma surgery and shock. Disclosed herein are methods for the prevention and treatment of ischemia and reperfusion injury with the administration of sulfatides. Also disclosed herein are methods of preventing and treating hepatic reperfusion injury by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the injury.

The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates to methods of reducing the likelihood of a patient at risk for non-alcoholic fatty liver diseases (NAFLD), including non-alcoholic steatohepatitis (NASH), or treating NAFLD or NASH including primary NASH, NASH secondary to liver transplantation (NASH post-liver transplantation) or cirrhosis represent alternative aspects of the present invention.

The invention provides a method for maintaining the survival and/or function of vascular endothelial cells in the in vitro preservation process and used preserving fluid. The method and the preservingfluid are suitable for storing various organs. The in vitro liver can survive to exceed 24h during the preservation by the organ preserving liquid and in the mechanical filling process; the liver microcirculation structure is complete; no obvious damage exists; the choleresis function is good; the liver synthesis and metabolism functions are good; the in vitro preservation time of the liver is greatly prolonged; the postoperative survival rate of later-period liver transplantation patients is improved.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).

Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and/or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

The invention discloses a SNP in KRT8 gene exon area and determination method thereof, and the SNP locus with G/T polymorphisms (GG) is at 12563 site of the eighth exon area of the KRT8 gene and has nucleotide sequences SEQ ID NO:1 and SEQ ID NO:2. The invention also provides a determination method of the SNP locus, and research and development of the polymorphisms can be applied to researches in the aspect of primary biliary cirrhosis, for example, control of primary biliary cirrhosis attack and hepatic cirrhosis degree or improvement of liver transplantation success rate.

Accurate self report strategies, biological state markers, combinations of alternative biomarkers, and combinations of biomarkers and self reports capable of monitoring alcohol consumption with a high sensitivity and specificity over a broad time spectrum are disclosed.

In particular, the use of ethyl sulfate (monoethylsulfate, molecular weight 126 g/mol, C₂H₅SO₄H) to elucidate ethanol intake is described in the context of screening monitoring in various settings, e.g. a) after liver transplantation b) methadone maintenance patients with hepatitis C and comorbid excessive alcohol use c) underage drinking d) rehabilitation programs for alcoholics motivational feedback to improve knowledge on drinking patterns differentiating moderate/social drinking from problematic/harmful drinking differential diagnosis (e.g. elevated transaminases) evaluating treatment programs and drug trials elucidating the role of neuropsychological impairment following alcoholisation (i.e. hangover state) which plays a major role in accidents, disclosing recent drinking in social drinkers in risky situations (driving, workplaces, pregnancy (fetal alcohol syndrome (FAS)), and general monitoring.

The invention relates to a metabotropic diagnosis kit used for detecting tacrolimus. The diagnosis kit comprises a reagent for detecting gene CYP3A4 rs2242480 SNP loci, a reagent for detecting gene CYP3A5 rs776746 SNP loci, and a reagent for detecting the total bilirubin content. The current clinical dosage of tacrolimus is determined according to the weight of patients, and different dosages of tacrolimus are needed for treatment so that different genotype patients can have the same target plasma concentration. By testing single nucleotide polymorphism (SNP) and clinical biochemical indicators of 170 pairs of liver transplantation donor CYP3A5 rs776746 loci and liver transplantation receptor CYP3A4 rs2242480 loci, the relation with tacrolimus metabolism is discussed, and the basis is provided for individualized drug administration of clinical liver transplantation patients.

The invention provides a drug for treating hepatocellular carcinoma. The drug comprises a glucagon-like peptide-1 receptor stimulant and/or a dipeptidyl peptidase 4 inhibitor. The invention further provides application of the glucagon-like peptide-1 receptor stimulant and/or dipeptidyl peptidase 4 inhibitor to preparation of a drug for preventing or treating hepatocellular carcinoma, to preparation of a drug for liver function recovery after liver transplantation, and to preparation of a drug for preventing liver cancer relapse after liver transplantation. The glucagon-like peptide-1 receptor stimulant and/or dipeptidyl peptidase 4 inhibitor generates a differential effect in a tissue specificity way, so as to inhibit cancer cell proliferation and promote cancer cell apoptosis, meanwhile, liver cells are protected against apoptosis, so that obesity-dependent liver cancer or non-dependent liver cancer can be treated or weakened.

The invention relates to an artificial intelligence technology and the intelligent medical treatment technology field, aims at solving a problem of an inaccurate research result caused by research onthe premise of assumption of one or more influence factors in the prior art, and provides a prognosis prediction system after liver transplantation. The system comprises a data acquisition module foracquiring clinical data, a database for storing the clinical data, a factor statistics module and a correlation analysis module, wherein the clinical data includes basic information of a patient, clinical indexes, intraoperative processing measures and prognosis conditions after the liver transplantation; the factor statistics module is used for carrying out statistical testing on the clinical data and obtaining an influence factor with relatively strong significance; and the correlation analysis module is used for analyzing and detecting correlation between the influence factor and the prognosis conditions after the liver transplantation so as to obtain a risk factor having significant statistical correlation with the prognosis conditions after the liver transplantation. The method is applied to prediction of the prognosis conditions after the liver transplantation of the patient.

The invention discloses CircRNA with the sequence shown as SEQ ID NO:1, and further discloses an RT-PCR primer for detecting the CircRNA. The CircRNA has the obvious expression differences before and after the liver cancer operation; the expression quantity at one day before the lung cancer operation is obviously raised through being compared with that in a healthy control group; the obvious reduction trend exists on the 1st day, the 3rd day and the 7th day after the liver transplantation operation. The existing clinic auxiliary diagnosis technology used for the liver cancer is not complete, so that the CircRNA has the potential used as a biomarker relevant to the liver cancer.

The invention belongs to the fields of biological and medical examination, and relates to microRNA (ribonucleic acid) specific expression profile and clinical application thereof. Tumor recurrence after liver transplantation for liver cancer can be judged by five miRNAs or comprehensive indexes of the microRNA specific expression profile, accuracy rate reaches 77%, further, tumor recurrence and prognosis conditions of an integral case group can be judged, tumor recurrence and prognosis conditions can also be judged for patients after Milan delamination of the patients by the aid of the 5 miRNAs or the comprehensive indexes, accordingly, the microRNA specific expression profile can be used for screening patients with high tumor recurrence risks after clinical liver transplantation for liver cancer, assists in judging prognosis and realizing early diagnosis of recurrence, and provides a basis for early intervention treatment and implementation of individualized treatment.

The invention discloses a stent used for portal vein stenosis after liver transplantation in children, and belongs to the field of medical devices. A stent main body consists of a plurality of annularsupports distributed along an axial direction, and two adjacent annular supports are connected by at least one connector. The stent main body is divided into three parts: a proximal end, a middle part and a distal end, the pipe diameter of the middle part is the smallest, and the pipe diameter of the distal end is the largest. According to the present invention, the stent has the advantages thatthe stenosis of diseased vessels which is caused by pipe diameter mismatch and mainly concentrates on diameter changes is treated, the adhesion property of the vessel distal end and the expansion property of the vessel proximal end can be improved, and the physiological adaptability of the stent can be improved; the combined area and friction between the stent and a portal vein stent can be increased, the stability of the stent can be increased, and the incidence of stent displacement can be reduced; and the change of the portal vein intracavitary hemodynamics can be decreased, the risk of restenosis after stent implantation can be reduced, and the occurrence of adverse events can be decreased.

The invention belongs to the technical field of pharmaceutical dosage forms and nano medicine preparation, and more particularly relates to a micelle loaded with Tacrolimus or pharmaceutical salts thereof, a lyophilized preparation as well as preparation methods and applications thereof. In order to achieve the clinical application of the micelle provided by the invention, the drug loading, the encapsulation rate and the stability of the preparation need to be ensured. The micelle is prepared from biodegradable polymer materials and Tacrolimus or pharmaceutical salts thereof in parts by weight: 1 part of Tacrolimus or pharmaceutical salts thereof and 1.5-99 parts of degradable polymer materials, wherein the degradable polymer materials are diblock polymer methoxy polyethylene glycol-polycaprolactone (the molecular weight ratio of MPEG to PCL is 0.5-2), and triblock polymer polycaprolactone-polyethylene glycol-polycaprolactone (the molecular weight ratio of PCL to PEG is 0.5-3). The micelle using Tacrolimus or pharmaceutical salts thereof or the lyophilized preparation of the micelle can be used in medicines for anti-rejection in liver transplantation, kidney transplantation, lung transplantation, corneal transplantation and other organ transplantations.